By the Numbers
A global company with a strong US footprint
Our US presence extends from coast to coast. Novartis campuses are designed to foster a world-class work environment and promote a culture of collaboration and innovation to help continually meet the evolving needs of our patients, customers and the communities we serve.
Novartis drives job creation and economic impact in the US
In 2019 Novartis offered jobs directly, as well as indirectly, as a buyer of goods and services from suppliers.
 |
 |
In 2019 Novartis US Group Companies contributed over USD 12 billion (reflecting direct payments made to suppliers, vendors and employees and the value of contributions supporting patient access to our medicines).
| Novartis US Group Companies’ 2018 Total Economic Impact in the US** | USD 12,220,291,598 |
|---|---|
| Payments for external Research & Development (R&D) contracted services in US. | USD 621,205,130 |
| Payments to US businesses for other contracted services. | USD 3,434,022,987 |
| Rebates to US Medicaid programs. | USD 1,501,695,072 |
| Value of medications provided at no cost to eligible US patients who had experienced financial hardship and had limited or no prescription drug coverage. | USD 2,689,787,296 |
Reimagining medicine through science and innovation
Over 5400 US-based scientists, physicians and other R&D professionals at Novartis are designing and developing new treatments with the potential to have a significant impact on lives. Together with colleagues across the globe, they are contributing to our industry-leading pipeline of therapies for serious diseases affecting millions of people.
Our consistent investment in research and development – USD 9.4 billion in 2019 alone, including USD 3.9 billion in the US – fuels our progress. It’s also a key pillar of our strategy to build a leading, focused medicines company powered by advanced therapy platforms and data science.
The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine for Novartis, working in concert with our Global Drug Development (GDD) group to bring important new treatments to patients in the US and worldwide. Our US research campuses are located in Cambridge, MA; Carlsbad, CA; East Hanover, NJ; Emeryville, CA; West Lafayette, IN; and San Diego, CA.
Our innovation engine sustains one of the industry’s most respected pipelines. In 2019 we had:
- 250 clinical trials with almost 17 300 randomized patients
- 3 breakthrough therapy designations from the US FDA
- 6 major US regulatory approvals received